To include your compound in the COVID-19 Resource Center, submit it here.

Celgene, Lannett cancer, generics news

The U.S. District Court of the Eastern District of Pennsylvania denied a motion by Celgene to dismiss a case brought by generics company Lannett seeking to require Celgene to provide Lannett with enough Thalomid thalidomide to conduct bioequivalence studies. The studies

Read the full 412 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers